Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Intellia Therapeutics (NTLA) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), Intellia Therapeutics (NTLA – Research Report) and Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teladoc (TDOC)
UBS analyst Kevin Caliendo maintained a Hold rating on Teladoc today and set a price target of $6.00. The company’s shares closed last Thursday at $5.35.
According to TipRanks.com, Caliendo is a 4-star analyst with an average return of
Teladoc has an analyst consensus of Moderate Buy, with a price target consensus of $7.18, a 50.8% upside from current levels. In a report issued on February 18, BTIG also maintained a Hold rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Intellia Therapeutics (NTLA)
Chardan Capital analyst Geulah Livshits maintained a Buy rating on Intellia Therapeutics today and set a price target of $26.00. The company’s shares closed last Thursday at $14.28.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $17.10, which is a 21.4% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a price target of $126.00. The company’s shares closed last Thursday at $64.75.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
Currently, the analyst consensus on Structure Therapeutics, Inc. Sponsored ADR is a Strong Buy with an average price target of $109.23, a 64.9% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $107.00 price target.
